Trial reportCardiovascular drugs and therapy2026
Ivabradine Versus Up-titrated Bisoprolol for Persistent Tachycardia After Primary PCI in Anterior STEMI: A Single-center, Open-label, Pragmatic RCT.
Trial report in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hexosamine Biosynthetic Pathway and Fatty Acid β-Oxidative Imbalance: A Key Mechanism by Which Abnormal Macrophage Lipophagy Promotes Atherosclerosis in Diabetes.Cardiovascular drugs and therapy · 2026Review
- Role of Circulating Microparticles in Impairing Endothelial Function and Activating Oxidative Stress Is Related to No-Reflow in STEMI.Cardiovascular therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPersistent sinus tachycardia after primary percutaneous coronary intervention (PCI) for anterior ST-segment elevation myocardial infarction (STEMI) predicts adverse left-ventricular (LV) remodeling and major adverse cardiovascular events (MACE), yet β-blocker up-titration is frequently limited by hypotension or LV dysfunction. We tested whether adjunctive ivabradine achieves superior heart-rate control and cardiac recovery compared with continued bisoprolol titration alone.
methodsIn this single-center, pragmatic, open-label, superiority randomized controlled trial, 140 patients with first-time anterior STEMI and resting heart rate ≥ 70 bpm despite maximally tolerated bisoprolol were assigned 1:1 to ivabradine add-on (5 mg twice daily) or continued bisoprolol titration. The primary endpoint was 12-month major adverse cardiovascular events (MACE). Secondary endpoints included change in resting heart rate from baseline to 12 months, left ventricular ejection fraction (LVEF), and B-type natriuretic peptide (BNP) levels.
resultsThroughout 12 months, ivabradine reduced heart rate by ≈ 10 bpm versus control (P < 0.05 for all time-points) and improved LVEF earlier (Δ + 5.7% at 6 months, P = 0.015; sustained at 12 months, P = 0.032). BNP declined more rapidly in the ivabradine group at 3 months (P = 0.038). MACE-free survival did not differ between groups (82.9% vs. 80.0%, log-rank P = 0.664). Age and baseline LVEF, but not ivabradine allocation, independently predicted MACE. Adverse events were infrequent.
conclusionsIn anterior-STEMI patients restricted by β-blocker ceiling, ivabradine add-on safely achieves sustained heart-rate reduction and early ventricular recovery without affecting 12-month MACE. Larger, blinded trials are warranted to confirm long-term efficacy and cost-effectiveness.
Indexed as
Identifiers
41144139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.